A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

September 28, 2007
Past Lexiva Treatment May Reduce Benefit From Prezista
A recent study reported by AIDSmap has found that some people who have developed drug resistance to the protease inhibitor (PI) Lexiva (fosamprenavir) may have a reduced benefit from another PI, Prezista (darunavir).
September 27, 2007
Ban on European Viracept Sales Lifted
The European Medicines Agency (EMEA) has announced that it is lifting its recent ban on the sale of Viracept (nelfinavir) in Europe, according to the Associated Press.
KP-1461: A New Approach to HIV Treatment Now in Studies
A completely new type of antiretroviral drug—KP-1461, manufactured by Koronis Pharmaceuticals—has entered the human testing phase.
September 26, 2007
Genetic Tests Could Help Reduce Sustiva Side Effects
Japanese researchers have found that some people can safely reduce their dose of Sustiva (efavirenz) and possibly reduce the chance of side effects.
September 25, 2007
High Rate of Kidney Problems in HIV
A high rate of kidney problems in HIV-positive people has been documented in a New York study.
Dry Skin More Common in Positive People
Dry skin is more common in people with HIV than in people who are HIV negative, according to a new study published in the journal AIDS.
September 24, 2007
Etravirine for NNRTI-Resistant HIV: Pooled DUET Study Results
A combined analysis of two Phase III clinical trials of etravirine suggests that the drug is promising for treatment-experienced patients, when combined with an optimized background regimen (OBR).
Activist Seek Fair Price for Isentress
A coalition of AIDS activists is calling on Merck & Co. Inc. to set a fair and reasonable price for their integrase inhibitor Isentress (raltegravir).
Maraviroc Gets EU Approval
Pfizer Inc announced today that the European Commission has approved the antiretroviral drug maraviroc for treatment-experienced patients in the European Union (EU).
September 21, 2007
Single-Dose PRO 140 Has Lasting Effects
Researchers once again reported promising results from an early study of PRO 140, an experimental HIV entry inhibitor.
48-Week Selzentry Data Show Promise for Drug-Resistant HIV
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
September 20, 2007
Wisdom for Women: An Expert's Take on HIV and Gender Differences
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research.
Selzentry Treatment Failure: The Impact of Tropism Changes
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s.
Two-Year Vicriviroc Benefit in Treatment-Experienced Patients
Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in treatment-experienced patients who combine the drug with an optimized background regimen (OBR). 
FDA Grants Priority Review for New NNRTI, Etravirine
The Food and Drug Administration (FDA) has granted priority review status for etravirine (also known as TMC125), according to an announcement by Tibotec Pharmaceuticals Ltd.
HIV Prevalence Declines in Pregnant Women in Zimbabwe
Of a new study presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago (ICAAC) this week, AIDSmap reports that the percentage of pregnant women who tested positive at a Zimbabwe hospital dropped by 41 percent between 1999 and 2007.
September 19, 2007
Coming Down the Pike: Expanding HIV Treatment Options
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every other week.
IL-2 May Delay Need for Antiretroviral Treatment
An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high and postpone their need to begin antiretroviral therapy.
Elvitegravir Study Highlights Value of Strong Background Regimen
Like all other promising experimental drugs, Gilead’s elvitegravir needs to be combined with other active drugs to which HIV is sensitive. 
New Data Explores Current Treatment Options
Peter Staley asks Dr. Joe Eron about the good news on a challenging drug -- newly-approved Selzentry -- and the very potent new protease inhibitor, Prezista.
September 18, 2007
Interview with a Hep C Activist & Survivor
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, about the latest in HCV treatment and prevention.
Heart Disease Risk Remains in Absence of HIV Treatment
There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is.
Prezista Shows Well in Patients New to Treatment
Prezista may be approved only for treatment-experienced patients, but new data suggest that it may have a lot to offer treatment newbies as well. 
Isentress Offers Long-Term Benefits for Drug-Resistant Patients
New follow-up data from a Phase II clinical trial evaluating Merck's integrase inhibitor Isentress suggests that the drug may offer long-term benefits to HIV-positive people with extensive treatment experience and drug resistance.
Secrets of a Long-Term Survivor
Peter Staley talks with Matt Sharp about his activism, his new regimen, and his facial lipo fix.
September 17, 2007
High Risk of Peripheral Artery Disease in HIV
Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.
Lexiva and Kaletra Comparable in Long-Term Study
New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness.
September 14, 2007
Pregnancy Protective Against HIV Disease Progression
New data published in the October 1 issue of the Journal of Infectious Diseases reveal that pregnancy may actually have protective health effects for HIV-positive women.
Skin Test Predicts Control of HPV
A new study shows that a simple skin-prick test may be useful in helping HIV-positive women determine if their immune systems are strong enough to control cancer-causing human papilloma virus (HPV) infection.
September 13, 2007
More Reports on Kidney Stones With Reyataz
A French study, published in the September 12 issue of Clinical Infectious Diseases, mirrors another report from the United States suggesting that kidney stones may be a side effect of the protease inhibitor Reyataz.
September 12, 2007
Lasting CD4 Increases With IL-2
Results from a new study justify scientists’ continuing interest in interleukin-2 (IL-2) therapy for HIV.
September 11, 2007
Pfizer Warns of Cancerous Impurity in Viracept
Pfizer is warning of a potentially cancerous impurity in Viracept and is now recommending that the protease inhibitor not be used by pregnant women and that children not start it.
HIV Damages Brain Despite Treatment
HIV treatment may not fully protect the brain or eliminate the risk of impaired brain functioning, according to a new study published in the September issue of AIDS and reported today by AIDSmap.
September 10, 2007
High-Fat Diets Affect Disease Progression
Scientists have added another strike against high-fat diets. A recent animal study in the Journal of Infectious Diseases suggests that a diet high in saturated fat and cholesterol may accelerate HIV disease progression.
September 07, 2007
Study Suggests Treating Hep C Before HIV
More evidence has arrived suggesting that treating hepatitis C (HCV) before HIV is a good idea, when possible.
September 06, 2007
Isentress Recommended for FDA Approval
As widely reported yesterday, an advisory committee to the FDA has unanimously voted to recommend approval for Isentress—the first of a new class of antiviral drug known as an integrase inhibitor—for use in people who’ve developed resistance to other drugs.
September 05, 2007
Promising New Nuke, Apricitabine
A new drug in development, apricitabine (ATC), may have moved another step closer toward inclusion in the arsenal of drugs approved to fight HIV. 
September 04, 2007
Needle-Free Device Improves Life for Fuzeon Users
People who use Fuzeon, an injectable antiviral drug known as a fusion inhibitor, should toss their syringes according to a study published in the October issue of the journal, HIV Medicine
Metformin Shows Little Lipodystrophy Benefit in Small Study
New research suggests that lipodystrophy sufferers should approach metformin with caution. 
Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?

February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.